Birmingham, West Midlands — (TechSonian) — 03/04/2014 — OmniVision Technologies, Inc. (NASDAQ:OVTI) shares moved up to a 2 month high after the strong quarterly results. Revenues for the third quarter of fiscal 2014 were $352.0 million. Net income in the third quarter was $30.6 million, or $0.54 per diluted share, as compared to net income of $26.3 million, or $0.47 per diluted share in the second quarter. In the last trading session, stock surged +3.82% and closed at $17.93 with the overall traded volume of 3.66 million shares. OVTI has earnings per share of $1.45. OmniVision Technologies, Inc. (OmniVision) designs, develops and markets integrated and semiconductor image-sensor devices.
Is OVTI a Buy after the Recent Price Movement? Find Out Here
EPAM Systems Inc (NYSE:EPAM) declined -23.63% with the closing price of $32.02. The overall volume in the last trading session was 3.62 million shares. Its fifty two week range was $20.50-$46.70. The total market capitalization remained $1.49 billion. EPAM is ahead its 52 week low with 56.20% and its last month price volatility remained 7.49%. Its target price was $42.83. EPAM has insider ownership of 0.20% with its institutional ownership remained 91.50%. Company’s current year earnings per share grew with 303.40% while the five year EPS growth rate was +32.20%.
Will EPAM Get Buyers Even After The Recent Rally? Find Out Here
Dyax Corp. (NASDAQ:DYAX) traded with the total volume of 3.61 million shares in the last trading session. DYAX reported the gain of +6.62% and its closing price was $10.31. DYAX has outstanding shares of 109.26 million with the total market cap of $1.13 billion. Dyax Corp., a biopharmaceutical company, engages in the identification, development, and commercialization of treatments for plasma kallikrein-mediated (PKM) angioedemas. It offers KALBITOR for the treatment of acute attacks of hereditary angioedema (HAE).
Is DYAX a Solid Investment at These Levels? Read This Report For Details
Dynavax Technologies Corporation (NASDAQ:DVAX) gained +1.61% and closed at $1.89 in the last trading session and its total traded volume was 3.54 million shares. DVAX has market cap of $496.36 million. Stock price 52 weeks high was $2.68. Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
What DVAX’s Charts Are Signaling for Traders? Find Out Her